Eli Lilly and Company announced approved updates of Humalog (insulin lispro injection [rDNA origin]) labeling from their supplemental NDA. The new labeling includes: continuous insulin infusion pump therapy in children ≥4 years of age with type 1 diabetes; extension of the time-in-use in the external pump reservoir to a maximum of seven days; and extension of the time-in-use of the infusion set and of the infusion set subcutaneous insertion site to a maximum of three days. Based on the updated label, people with type 1 diabetes using Humalog for pump therapy can use the insulin in the pump reservoir for up to seven days and should change the infusion set and infusion set insertion site at least every three days. The previous label indicated that Humalog in the external insulin pump reservoir should be replaced and a new infusion site selected every 48 hours or less.

Humalog is currently approved and available in multiple formulations to treat patients with diabetes.

For more information call (800) LillyRx or visit www.humalog.com.